Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous N-acetylcysteine vs placebo for mild and moderate ARDS caused by COVID-19
IRCT20120215009014N355Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) comparing Intravenous N-acetylcysteine with Placebo (2 arms). Started Jun 2020; status: completed.
02
Drugs
acetylcysteine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20120215009014N355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N355.